These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33447944)

  • 21. The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?
    Bos AC; Passé KM; Mouton JW; Janssens HM; Tiddens HA
    J Cyst Fibros; 2017 Jan; 16(1):13-23. PubMed ID: 28254026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006961. PubMed ID: 18646176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
    Jain K; Wainwright C; Smyth AR
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009530. PubMed ID: 24363033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J; Nevitt SJ
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD002009. PubMed ID: 28349527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.
    Elphick HE; Scott A
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD002007. PubMed ID: 27907224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
    Jain K; Wainwright C; Smyth AR
    Cochrane Database Syst Rev; 2016 Jan; (1):CD009530. PubMed ID: 26797965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin pharmacokinetics in adult cystic fibrosis.
    Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
    Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
    Döring G; Conway SP; Heijerman HG; Hodson ME; Høiby N; Smyth A; Touw DJ
    Eur Respir J; 2000 Oct; 16(4):749-67. PubMed ID: 11106223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
    Palser S; Smith S; Nash EF; Agarwal A; Smyth AR
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.
    Rees VE; Deveson Lucas DS; López-Causapé C; Huang Y; Kotsimbos T; Bulitta JB; Rees MC; Barugahare A; Peleg AY; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Nair CG; Chao C; Ryall B; Williams HD
    Lett Appl Microbiol; 2013 Feb; 56(2):149-54. PubMed ID: 23206221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.
    Nolt VD; Pijut KD; Autry EB; Williams WC; Burgess DS; Burgess DR; Arora V; Kuhn RJ
    Pediatr Pulmonol; 2019 Jan; 54(1):33-39. PubMed ID: 30507069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.
    Stefani S; Campana S; Cariani L; Carnovale V; Colombo C; Lleo MM; Iula VD; Minicucci L; Morelli P; Pizzamiglio G; Taccetti G
    Int J Med Microbiol; 2017 Sep; 307(6):353-362. PubMed ID: 28754426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
    Ryan G; Mukhopadhyay S; Singh M
    Cochrane Database Syst Rev; 2003; (3):CD001021. PubMed ID: 12917897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.